Suppr超能文献

进行性核上性麻痹(PSP)表型与生存的关联:一项脑库研究。

Association of PSP phenotypes with survival: A brain-bank study.

作者信息

Guasp Mar, Molina-Porcel Laura, Painous Celia, Caballol Nuria, Camara Ana, Perez-Soriano Alexandra, Sánchez-Gómez Almudena, Garrido Alicia, Muñoz Esteban, Marti Maria Jose, Valldeoriola Francesc, Grau Oriol, Gelpí Ellen, Respondek Gesine, Höglinger Guenter H, Compta Yaroslau

机构信息

Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.

Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Catalonia, Spain.

出版信息

Parkinsonism Relat Disord. 2021 Mar;84:77-81. doi: 10.1016/j.parkreldis.2021.01.015. Epub 2021 Feb 2.

Abstract

INTRODUCTION

The MDS-PSP criteria expand the phenotypic spectrum of PSP by adding to Richardson's syndrome (PSP-RS) other presentations such as PSP-parkinsonism (PSP-P), PSP-pure-gait-freezing (PSP-PGF), PSP-speech-language (PSP-SL), PSP-frontal (PSP-F), PSP-postural-instability (PSP-PI) and PSP-corticobasal-syndrome (PSP-CBS). Evidence about the prognostic differences between PSP phenotypes is scarce and focused on PSP-RS vs. non-PSP-RS. Using a brain-bank cohort we assessed PSP survival not only in PSP-RS vs. non-PSP-RS, but also in PSP-RS + cortical vs. subcortical phenotypes. Besides, we assessed sensitivity and specificity of the MDS-PSP criteria in of PSP and other degenerative parkinsonisms.

METHODS

We retrospectively applied the MDS-PSP diagnostic criteria to 32 definite PSP cases and 30 cases with other degenerative parkinsonian syndromes (Parkinson's disease [PD; n = 11], multiple system atrophy [MSA; n = 11], corticobasal degeneration [CBD; n = 8]). We conducted survival statistics in neuropathologically confirmed PSP cases considering PSP-RS vs. non-PSP-RS and PSP-RS + PSP-cortical (PSP-F + PSP-SL + PSP-CBS) vs. PSP-subcortical (PSP-P + PSP-PGF) phenotypes. We also adjusted survival analyses for PSP tau scores.

RESULTS

Diagnostic sensitivity was 100% and specificity ranged from 47% to 87% when excluding cases that met the "suggestive of PSP" definition early in their disease course but with other clinical features better matching with a non-PSP pathological diagnosis. Survival was significantly shorter in PSP-RS vs. non-PSP-RS cases, but it was more markedly shorter in PSP-RS + PSP-cortical vs. PSP-subcortical, independently of PSP tau scores, which were not associated with survival.

CONCLUSIONS

PSP-subcortical phenotypes appear to have longer survival than PSP-RS and cortical phenotypes. This might be of prognostic relevance when informing patients upon clinical diagnosis.

摘要

引言

MDS-PSP标准通过在理查森综合征(PSP-RS)基础上增加其他表现型,如帕金森型PSP(PSP-P)、单纯步态冻结型PSP(PSP-PGF)、语言型PSP(PSP-SL)、额叶型PSP(PSP-F)、姿势不稳型PSP(PSP-PI)和皮质基底节综合征型PSP(PSP-CBS),扩展了PSP的表型谱。关于PSP各表型预后差异的证据稀少,且主要集中在PSP-RS与非PSP-RS之间。我们利用一个脑库队列,不仅评估了PSP-RS与非PSP-RS患者的生存期,还评估了PSP-RS加皮质型与皮质下型表型患者的生存期。此外,我们评估了MDS-PSP标准对PSP及其他退行性帕金森综合征的敏感性和特异性。

方法

我们对32例确诊的PSP病例和30例其他退行性帕金森综合征患者(帕金森病[PD;n = 11]、多系统萎缩[MSA;n = 11]、皮质基底节变性[CBD;n = 8])进行回顾性应用MDS-PSP诊断标准。我们对经神经病理学证实的PSP病例进行生存统计,考虑PSP-RS与非PSP-RS以及PSP-RS加皮质型(PSP-F + PSP-SL + PSP-CBS)与皮质下型(PSP-P + PSP-PGF)表型。我们还对PSP tau评分进行了生存分析调整。

结果

当排除疾病早期符合“疑似PSP”定义但其他临床特征更符合非PSP病理诊断的病例时,诊断敏感性为100%,特异性范围为47%至87%。PSP-RS患者的生存期明显短于非PSP-RS患者,但PSP-RS加皮质型患者的生存期比皮质下型患者更显著缩短,且与PSP tau评分无关,PSP tau评分与生存期无关联。

结论

PSP皮质下型表型的生存期似乎比PSP-RS和皮质型表型更长。这在临床诊断时告知患者预后情况可能具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验